The use of alpha-adrenergic blockers in benign prostatic obstruction.
about
Medical treatment of benign prostatic hyperplasia.Pharmacotherapy for benign prostatic hyperplasia.Prevention of urinary retention with phenoxybenzamine during epidural morphine.Lower urinary tract disease: what are we trying to treat and in whom?Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasiaEndocrine and adrenergic pharmacological intervention in diseases of the prostateOutcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH)Role of alpha blocker therapy in chronic prostatitis/chronic pelvic pain syndrome: limited options with promising results.Treatment options for benign prostatic hyperplasia.Impacts of the quinazoline-based alpha1-antagonist, terazosin, and of the sulfonamide derivative, tamsulosin, on serum prostate-specific antigen and prostate volume.Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importanceAdvances in the design and discovery of drugs for the treatment of prostatic hyperplasia.Use of meta-analytic results to facilitate shared decision makingA comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargementPharmacologic management of benign prostatic hyperplasia--changing times.Catheterisation for nephrectomy?Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery.Inhibition of Prostate Smooth Muscle Contraction by Inhibitors of Polo-Like Kinases.
P2860
Q33588534-DD5E5990-3B22-49E1-B904-BB3A73E25458Q33608293-A073C134-1A6F-4E5F-ABFD-98208C60D758Q34556135-CA317ECB-8DDD-4999-8569-C1B6F9E351A0Q35545715-89AB1421-481A-445C-8D0E-1660689613F6Q35737705-0CEE8C0D-8AE7-4334-BF3B-44892624C15BQ35803015-047A2184-75A4-48DB-AA87-DD70CCEFD8CCQ35919193-572F0BD0-06D6-46A4-8882-10663B0F8D13Q36261483-769FEB26-C4F1-45A9-BB0C-5B39462F5E10Q36479670-03E2D9E5-B953-46A0-9E55-5ADB46B4A4C4Q36854494-DE364B41-2609-4D43-9A57-0553EBD7F07CQ37432103-D49016D7-FEDC-4E82-B653-C1EF3B73AB15Q38105608-7504996C-372F-46C4-8A86-F3B8E4510EDAQ39274525-94B36B48-E4E9-4EB2-A85D-7627EDDE926AQ41859727-E4416CC2-A45C-419B-A84C-3B5BB683F17FQ41921982-4C05483E-8607-4279-971D-192112C8214AQ42333609-94DE3C5C-937B-42F2-9823-73A26A77ED3DQ42370475-CFB65CAA-9868-4172-8082-618E2F3815EEQ55361601-E7B0CA4A-66AC-4190-860A-853A96C9E4B4
P2860
The use of alpha-adrenergic blockers in benign prostatic obstruction.
description
1976 nî lūn-bûn
@nan
1976年の論文
@ja
1976年論文
@yue
1976年論文
@zh-hant
1976年論文
@zh-hk
1976年論文
@zh-mo
1976年論文
@zh-tw
1976年论文
@wuu
1976年论文
@zh
1976年论文
@zh-cn
name
The use of alpha-adrenergic blockers in benign prostatic obstruction.
@en
The use of alpha-adrenergic blockers in benign prostatic obstruction.
@nl
type
label
The use of alpha-adrenergic blockers in benign prostatic obstruction.
@en
The use of alpha-adrenergic blockers in benign prostatic obstruction.
@nl
prefLabel
The use of alpha-adrenergic blockers in benign prostatic obstruction.
@en
The use of alpha-adrenergic blockers in benign prostatic obstruction.
@nl
P2093
P1476
The use of alpha-adrenergic blockers in benign prostatic obstruction.
@en
P2093
P304
P356
10.1111/J.1464-410X.1976.TB03013.X
P577
1976-08-01T00:00:00Z